Effect of silymarin on hepatic function of patients with unresectable hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization

TMUIR > College of Medicine > Department of Medicine > Department of Radiology > Periodical Article > Item 987654321/1169

Please use this identifier to cite or link to this item: http://libir.tmu.edu.tw/handle/987654321/1169

Title:	Effect of silymarin on hepatic function of patients with unresectable hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization
Authors:	李志明;邱仲峰;梁庭繼 Lee CM;Leung TK;Chang CC;Kuo YC;Chiou JF;Wang HJ;Chen YY
Contributors:	醫學系放射線學科
Date:	2008
Issue Date:	2009-08-14 12:58:32 (UTC+8)
Abstract:	經肝動脈栓塞合併化學治療是治療無法切除之肝腫瘤常用的方法。Silymarin是水飛薊植物的衍生物，它被廣泛地使用在慢性肝疾病上。在台灣，有一些醫師會建議病患在進行經肝動脈栓塞合併化學治療後，服用silymarin來作為保肝劑。本研究探討silymarin在此模式下之有效性。本研究共有244位接受經肝動脈栓塞合併化學治療之病患，這些病患在術前之Child-Pugh classification皆無顯著差異。其中111位在經肝動脈栓塞合併化學治療後，每日服用280毫克的silymarin持續兩週，另外133位在治療後不服用silymarin。紀錄病患術前、術後第二、四、六天及二、三、四、五週之肝功能相關數據。結果顯示，兩組病患之肝功能（包括ALT、AST、鹼性磷酸酶、總膽紅素、白蛋白、乳糖脫氫酶）在各個不同的時間點時，皆無顯著差異。每日服用280毫克的silymarin持續兩週，並不能顯著改善經肝動脈栓塞合併化學治療後病患之肝功能，顯示silymarin投與之劑量及時間長短須經更嚴密的設計。 Transcatheter hepatic arterial chemoembolization (TACE) is common treatment for unresectable hepatocellular carcinoma. Silymarin, derived from milk thistle, is widely used internationally for chronic liver disease. Some Taiwanese physicians prescribe silymarin as a hepatoprotective agent after TACE, although there is no evidence on its efficacy in this setting. Retrospectively compare two groups of patient undergoing TACE at our institution: 111 given silymarin postoperatively and 133 who underwent the same procedure and received similar postoperative care but were not given silymarin. The postoperative liver function was evaluated. Patients prescribed silymarin took 280 mg orally daily for two weeks. Liver function tests were checked at baseline and on post-TACE days 2, 4, and 6 and weeks 2-5. Groups were comparable for age, gender, and Child-Pugh class. There were no significant differences between the two groups at different time points in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin and lactate dehydrogenase. Oral silymarin did not accelerate recovery of hepatic function following TACE; there is no basis for its use in this setting.
Relation:	Chin J Radiol.(33):137-141.
Data Type:	article
Appears in Collections:	[Department of Radiology] Periodical Article

Files in This Item:

File	Size	Format
H-10.pdf	336Kb	Adobe PDF	143	View/Open
全文.txt	0Kb	Text	198	View/Open
摘要.pdf	71Kb	Adobe PDF	149	View/Open

Loading...